search
Back to results

OSA Recurrence in CPAP Withdrawal

Primary Purpose

OSA

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
CPAP withdrawal
Sponsored by
Guy's and St Thomas' NHS Foundation Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for OSA focused on measuring OSA, CPAP, upper airway collapse, neural respiratory drive

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  • Age ≥18-80 years. Objectively confirmed OSA with an apnoea-hypopnoea- index (AHI) or an oxygen desaturation index (ODI) of ≥20/h at the time of diagnosis (obstructive events).
  • Effectively treated with CPAP for > 6 months (AHI on CPAP < 5/h, CPAP usage > 4 hours/night > 70% of the days).

Exclusion criteria:

  • Moderate to severe obstructive (FEV1/FVC < lower limit of normal and FEV1 < 70% predicted) or restrictive lung disease (FVC < 60% predicted).
  • Daytime pCO2 > 6 kPa (45 mmHg).
  • Central Sleep Apnoea/Cheyne Stokes Respiration. Unstable heart failure, untreated coronary artery disease, severe arterial hypertension (resting blood pressure >180/110 mmHg).
  • Co-existing non-respiratory sleep disorder (by history).
  • Opioid or sedative use. Alcohol abuse.
  • Current professional driver or comparable profession.

Sites / Locations

  • Guys and St Thomas NHS Foundation Trust

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

CPAP withdrawal

Arm Description

Short-term withdrawal of CPAP therapy in moderate to severe OSA (intervention)

Outcomes

Primary Outcome Measures

Change in neural respiratory drive (NRD) during sleep upon CPAP therapy withdrawal
Electromyography of respiratory muscles as measure of neural respiratory drive

Secondary Outcome Measures

Pharyngeal critical occlusion pressure during sleep (Pcrit)
Measures of upper airway collapsibility (cmH2O)
Forced oscillation technique (FOT)
Measure of (upper) airway resistance
Negative expiratory pressure (NEP)
Measure of (upper) airway resistance and collapsibility (cmH2O)
Pharyngeal oedema
Transcervical ultrasound (mm)
Forced expiratory volume in 1 second
Spirometry
Forced vital capacity
Spirometry
Recurrence pattern of OSA defined by the nightly obstructive respiratory events (apnoea-hypopnoea-index)
Polysomnography (events/hour)
Recurrence pattern of OSA defined by the nightly obstructive respiratory events (oxygen desaturation index)
Nightly home pulse oximetry (events/hour)
Home and office blood pressure
Blood pressure (mmHg)
Home and office heart rate
Heart rate (bpm)
Epworth Sleepiness Scale Score (ESS)
Questionnaire for subjective sleepiness (Points)
Fatigue Severity Sclae (FSS)
Questionnaire for subjective sleepiness (Points)
Stanford Sleepiness Scale (SSS)
Questionnaire for subjective sleepiness (Points)
Functional Outcomes of Sleep Questionnaire (FOSQ)
Quality of life questionnaire
Association between ODI (recurrence pattern of OSA) and neural respiratory drive (NRD)
Multivariate Regression modelling with ODI as dependent variable

Full Information

First Posted
March 7, 2018
Last Updated
March 14, 2022
Sponsor
Guy's and St Thomas' NHS Foundation Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT03472612
Brief Title
OSA Recurrence in CPAP Withdrawal
Official Title
Pathophysiology of Obstructive Sleep Apnoea Recurrence During Continuous Positive Airway Pressure Therapy Withdrawal
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
April 9, 2018 (Actual)
Primary Completion Date
June 30, 2019 (Actual)
Study Completion Date
October 1, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Guy's and St Thomas' NHS Foundation Trust

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Continuous positive airway pressure (CPAP) therapy is the most effective Treatment for obstructive sleep apnoea (OSA ). However, adherence to CPAP is often limited. There are established and emerging treatment alternatives to CPAP available, however, they are usually less effective than CPAP. To develop novel treatment methods and to predict who will respond to which treatment, the mechanism underlying obstructive sleep apnoea and different patient types should be described. Especially the contribution of the upper airway function and central respiratory control should be studied for this purpose. In a prospective interventional study, patients with OSA effectively treated with CPAP will undergo physiologic measurements during a two week period off CPAP to define the pathophysiological mechanisms associated with OSA recurrence. This knowledge could facilitate individually tailored treatment and improve therapy adherence and patient outcomes.
Detailed Description
Obstructive sleep apnoea (OSA) is a highly prevalent sleep-related breathing disorder characterised by a repetitive collapse of the pharynx during sleep, which results in apnoea or hypopnoea associated with oxygen desaturations and arousal from sleep. Continuous positive airway pressure (CPAP) is the gold standard treatment. Treatment success depends on regular CPAP usage. However, low adherence to CPAP is a frequent problem. It has recently been shown that OSA does not re-occur immediately in all OSA patients upon CPAP therapy withdrawal and that there are different patterns of recurrence of OSA as indicated by repeated sleep studies. So far, the mechanisms of OSA recurrence upon CPAP therapy withdrawal are incompletely understood. Upper airway collapsibility and neuromuscular tone, pharyngeal oedema and inflammation, neural respiratory drive, sleep stage and position may play a role. In a prospective interventional study, patients with OSA effectively treated with CPAP will undergo physiologic measurements during a two week period off CPAP to define the pathophysiological mechanisms associated with OSA recurrence. In particular, we will investigate the effects of CPAP withdrawal on neural respiratory drive and upper airway function. Inpatient sleep studies and assessments will be performed at baseline (day 0) on CPAP and at follow-up upon CPAP withdrawal (day 14). At the end of the trial patients will return to their established CPAP therapy. We hypothesise that CPAP withdrawal results in different patterns of OSA recurrence defined by neural respiratory drive and upper airway function. The aim of the proposed project is to study the mechanisms of OSA recurrence by using a validated CPAP withdrawal model. Knowledge on recurrence patterns and different phenotypes of OSA could facilitate individually tailored treatment of OSA and improved therapy adherence and patient outcomes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
OSA
Keywords
OSA, CPAP, upper airway collapse, neural respiratory drive

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
25 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CPAP withdrawal
Arm Type
Experimental
Arm Description
Short-term withdrawal of CPAP therapy in moderate to severe OSA (intervention)
Intervention Type
Other
Intervention Name(s)
CPAP withdrawal
Intervention Description
Short-term withdrawal of CPAP therapy in moderate to severe OSA
Primary Outcome Measure Information:
Title
Change in neural respiratory drive (NRD) during sleep upon CPAP therapy withdrawal
Description
Electromyography of respiratory muscles as measure of neural respiratory drive
Time Frame
2 weeks
Secondary Outcome Measure Information:
Title
Pharyngeal critical occlusion pressure during sleep (Pcrit)
Description
Measures of upper airway collapsibility (cmH2O)
Time Frame
2 weeks
Title
Forced oscillation technique (FOT)
Description
Measure of (upper) airway resistance
Time Frame
2 weeks
Title
Negative expiratory pressure (NEP)
Description
Measure of (upper) airway resistance and collapsibility (cmH2O)
Time Frame
2 weeks
Title
Pharyngeal oedema
Description
Transcervical ultrasound (mm)
Time Frame
2 weeks
Title
Forced expiratory volume in 1 second
Description
Spirometry
Time Frame
2 weeks
Title
Forced vital capacity
Description
Spirometry
Time Frame
2 weeks
Title
Recurrence pattern of OSA defined by the nightly obstructive respiratory events (apnoea-hypopnoea-index)
Description
Polysomnography (events/hour)
Time Frame
2 weeks
Title
Recurrence pattern of OSA defined by the nightly obstructive respiratory events (oxygen desaturation index)
Description
Nightly home pulse oximetry (events/hour)
Time Frame
2 weeks
Title
Home and office blood pressure
Description
Blood pressure (mmHg)
Time Frame
2 weeks
Title
Home and office heart rate
Description
Heart rate (bpm)
Time Frame
2 weeks
Title
Epworth Sleepiness Scale Score (ESS)
Description
Questionnaire for subjective sleepiness (Points)
Time Frame
2 weeks
Title
Fatigue Severity Sclae (FSS)
Description
Questionnaire for subjective sleepiness (Points)
Time Frame
2 weeks
Title
Stanford Sleepiness Scale (SSS)
Description
Questionnaire for subjective sleepiness (Points)
Time Frame
2 weeks
Title
Functional Outcomes of Sleep Questionnaire (FOSQ)
Description
Quality of life questionnaire
Time Frame
2 weeks
Title
Association between ODI (recurrence pattern of OSA) and neural respiratory drive (NRD)
Description
Multivariate Regression modelling with ODI as dependent variable
Time Frame
2 weeks
Other Pre-specified Outcome Measures:
Title
Association between different measures of (upper) airway function, namely Pcrit, FOT, NEP and FEV1/FVC
Description
Correlation analyses
Time Frame
2 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Age ≥18-80 years. Objectively confirmed OSA with an apnoea-hypopnoea- index (AHI) or an oxygen desaturation index (ODI) of ≥20/h at the time of diagnosis (obstructive events). Effectively treated with CPAP for > 6 months (AHI on CPAP < 5/h, CPAP usage > 4 hours/night > 70% of the days). Exclusion criteria: Moderate to severe obstructive (FEV1/FVC < lower limit of normal and FEV1 < 70% predicted) or restrictive lung disease (FVC < 60% predicted). Daytime pCO2 > 6 kPa (45 mmHg). Central Sleep Apnoea/Cheyne Stokes Respiration. Unstable heart failure, untreated coronary artery disease, severe arterial hypertension (resting blood pressure >180/110 mmHg). Co-existing non-respiratory sleep disorder (by history). Opioid or sedative use. Alcohol abuse. Current professional driver or comparable profession.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joerg Steier, MD Ph
Organizational Affiliation
Guy's and St Thomas' NHS Foundation Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
Guys and St Thomas NHS Foundation Trust
City
London
ZIP/Postal Code
SE1 7EH
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

OSA Recurrence in CPAP Withdrawal

We'll reach out to this number within 24 hrs